GMT Capital Corp Has $7.33 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)

GMT Capital Corp cut its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 65.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 285,136 shares of the company's stock after selling 543,900 shares during the period. NewAmsterdam Pharma accounts for approximately 0.4% of GMT Capital Corp's portfolio, making the stock its 27th biggest holding. GMT Capital Corp owned 0.31% of NewAmsterdam Pharma worth $7,328,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in NAMS. National Bank of Canada FI bought a new position in shares of NewAmsterdam Pharma during the 4th quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in NewAmsterdam Pharma during the fourth quarter valued at about $80,000. KLP Kapitalforvaltning AS acquired a new position in NewAmsterdam Pharma in the 4th quarter valued at approximately $154,000. Barclays PLC lifted its position in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after acquiring an additional 7,199 shares during the period. Finally, HB Wealth Management LLC acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $224,000. Institutional investors and hedge funds own 89.89% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on NAMS shares. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research note on Monday, March 3rd. Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. HC Wainwright reissued a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Scotiabank raised their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $43.33.

Insiders Place Their Bets

In related news, Director James N. Topper bought 4,005 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was bought at an average cost of $21.02 per share, with a total value of $84,185.10. Following the completion of the purchase, the director now owns 3,012,434 shares in the company, valued at approximately $63,321,362.68. The trade was a 0.13 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Stock Up 3.3 %

Shares of NAMS stock opened at $16.79 on Wednesday. The company has a market capitalization of $1.84 billion, a P/E ratio of -6.46 and a beta of -0.01. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29. The firm has a 50-day moving average price of $19.76 and a 200 day moving average price of $21.23.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Want to see what other hedge funds are holding NAMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewAmsterdam Pharma (NASDAQ:NAMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.